ALX Oncology Holdings Inc. (ALXO) Stock Grade

About ALX Oncology Holdings Inc.'s fundamentals

ALX Oncology Holdings Inc. is a small-cap biotechnology company with a market capitalization of $60.6 million that reported no revenue growth year-over-year, with zero net margin in its latest period. The company posted a net loss in its most recent annual statement and does not pay a dividend. Standard profitability metrics like P/E ratio and return on equity are not applicable given the company's loss position, which is typical for early-stage biotech firms still in development phases.